Open Heart: Tofacitinib in the treatment of cardiac sarcoidosis: towards steroid-sparing disease management Background Cardiac sarcoidosis (CS) creates complex treatment challenges, especially for patients who fail to respond to immunosuppressive drugs, including second-line tumour necrosis factor ... The American Journal of Managed Care: Reviewing ERS Treatment Guidelines in Sarcoidosis Task force members from the European Respiratory Society evaluated available evidence for treatment of various manifestations of sarcoidosis but said their recommendations were not the last word. As ...
Healio: ‘Treatment is not one size fits all’: Sarcoidosis management must be individualized ‘Treatment is not one size fits all’: Sarcoidosis management must be individualized Healio: Rare organ sarcoidosis marker for more severe disease, but infrequently requires treatment Rare organ sarcoidosis marker for more severe disease, but infrequently requires treatment NEW YORK CITY -- Patients with longstanding sarcoidosis and skin involvement had dramatic improvement after 6 months of treatment with the Janus kinase (JAK) inhibitor tofacitinib (Xeljanz), a small ... Prednisone is recommended as the first-line treatment for pulmonary sarcoidosis, but this steroid causes a number of unwanted side effects. Now new research published at the ATS 2025 International ... Business Wire: Kinevant Sciences Announces First Patient Dosed in Phase 2 Study of Namilumab for the Treatment of Pulmonary Sarcoidosis (RESOLVE-Lung) Kinevant Sciences Announces First Patient Dosed in Phase 2 Study of Namilumab for the Treatment of Pulmonary Sarcoidosis (RESOLVE-Lung)
